Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures
Shervin Assassi(University of Houston), Keith M. Sullivan(Duke Medical Center), Maureen D. Mayes(The University of Texas Health Science Center), Chiara Bellocchi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Virginia Pascual(Cornell University), Monique Hinchcliff(Yale University), Lynette Keyes-Elstein(National Institute of Allergy and Infectious Diseases), Daniel E. Furst(University of California, Los Angeles), Paul K. Wallace(Roswell Park Comprehensive Cancer Center), Richard A. Nash(Colorado Blood Cancer Institute), Guocai Chen(The University of Texas Health Science Center at Houston), Leslie J. Crofford(Vanderbilt University Medical Center), Binwu Ying(Sichuan University), W. Jim Zheng(The University of Texas Health Science Center at Houston), Xuan Wang(Anhui University of Finance and Economics), Jacob Turner(Stephen F. Austin State University), Peter A. McSweeney(Mesoblast (United States)), Beverly Welch(National Institute of Allergy and Infectious Diseases), Ashley Pinckney(National Institute of Allergy and Infectious Diseases), Ellen Goldmuntz(National Institute of Allergy and Infectious Diseases), John Varga(Michigan Medicine)
Cited by 68
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k